Federal grants to Biotherapeutics, Inc.
Biotherapeutics, Inc. in Blacksburg, Virginia received $9.0 million in federal grants from fiscal 2021 to 2025, across 19 awards. Its largest program was Arthritis, Musculoskeletal and Skin Diseases Research, with $2.7 million. In fiscal 2025 it was awarded $3.2 million.
From USAspending.gov award records, updated October 31, 2026.
- Grants, FY 2021 to 2025$9.0 million
- Awards19
- Awarded in FY 2025$3.2 million
- Largest award$1.9 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 6 | $2.4 million |
| FY 2022 | 1 | $563,659 |
| FY 2023 | 6 | $2.0 million |
| FY 2024 | 3 | $944,921 |
| FY 2025 | 5 | $3.2 million |
Programs that fund Biotherapeutics, Inc.
| Program | Awards | Amount |
|---|---|---|
| Arthritis, Musculoskeletal and Skin Diseases Research | 4 | $2.7 million |
| Allergy and Infectious Diseases Research | 6 | $2.7 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 4 | $1.9 million |
| Cardiovascular Diseases Research | 4 | $1.4 million |
| Scientific Research - Combating Weapons of Mass Destruction | 1 | $339,788 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 18 | $8.7 million |
| Department of Defense | 1 | $339,788 |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| A first-in-class topical immunoregulatory therapeutic for psoriasis - a first-in-class topical immunoregulatory therapeutic for psoriasis biotherapeutics, inc (BTI) is an emerging private biotech company that synergistically combines the power of advanced computational modeling with translational ex | Arthritis, Musculoskeletal and Skin Diseases Research | September 22, 2025 | $1.9 million |
| Novel immunoregulatory therapeutics for systemic lupus erythematosus - novel immunoregulatory drugs for systemic lupus erythematosus biotherapeutics, inc (BTI) is an emerging biotech company that synergistically combines the power of advanced computational modeling with translational experimentation | Allergy and Infectious Diseases Research | June 27, 2022 | $1.1 million |
| Validation of immunometabolic NLRX1 therapeutics for ibd | Diabetes, Digestive, and Kidney Diseases Extramural Research | November 13, 2020 | $804,677 |
| Effects of abscisic acid on insulin sensitivity | Diabetes, Digestive, and Kidney Diseases Extramural Research | May 27, 2021 | $419,987 |
| Targeting the immunometabolic hub NLRX1 as a novel therapeutic for asthma - targeting the immunometabolic hub NLRX1 as a novel therapeutic for allergic asthma biotherapeutics inc (BTI) is an emerging biotech company that synergistically combines the power of advanced computational modeling with tran | Cardiovascular Diseases Research | July 27, 2021 | $361,510 |
| Next-gen oral therapeutics for type 2 diabetes - next-gen oral therapeutics for type 2 diabetes biotherapeutics inc (BTI) is a clinical-stage biotech company that synergistically combines the power of advanced computational modeling with translational and clinical experimentation to accelerate the d | Diabetes, Digestive, and Kidney Diseases Extramural Research | June 20, 2025 | $359,625 |
| Immunoregulatory therapeutics for ulcerative colitis - immunoregulatory therapeutics for ulcerative colitis biotherapeutics, inc (BTI) is an emerging biotech company that synergistically combines the power of advanced computational modeling with translational experimentation to accelerate the develo | Diabetes, Digestive, and Kidney Diseases Extramural Research | April 14, 2023 | $356,068 |
| Development of novel immunoregulatory therapeutics for asthma - development of novel immunoregulatory therapeutics for asthma biotherapeutics inc (BTI) is an emerging biotech company that synergistically combines the power of advanced computational modeling with translational experimentation to acce | Cardiovascular Diseases Research | September 17, 2024 | $355,935 |
| The next wave of asthma therapeutics - the next wave of asthma therapeutics biotherapeutics inc (BTI) is an emerging biotech company that synergistically combines the power of advanced computational modeling with translational experimentation to accelerate the development of novel products for preci | Cardiovascular Diseases Research | January 14, 2025 | $347,608 |
| Computational modeling of immune responses to clostridium difficile infection for predicting therapeutic efficacy | Scientific Research - Combating Weapons of Mass Destruction | May 5, 2021 | $339,788 |
Questions people ask
How much federal grant money does Biotherapeutics, Inc. get?
$9.0 million in 19 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives Biotherapeutics, Inc. the most?
The Department of Health and Human Services, with $8.7 million in 18 awards. The Department of Defense follow.
What is Biotherapeutics, Inc.'s largest federal grant?
$1.9 million under Arthritis, Musculoskeletal and Skin Diseases Research, with its first action in the period on September 22, 2025. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund Biotherapeutics, Inc.?
Its largest are Arthritis, Musculoskeletal and Skin Diseases Research, Allergy and Infectious Diseases Research and Diabetes, Digestive, and Kidney Diseases Extramural Research.
Other grant recipients in Blacksburg
- Virginia Polytechnic Institute & State University
- Town of Blacksburg
- Virginia Tech Montgomery Regional Airport Authority
- Virginia Rural Health Association
- Edward Via Virginia College of Osteopathic Medicine
- New River Valley Community Services
- Cytorecovery Inc
- The Enabled Manufacturing LLC
Largest federal grant recipients in Virginia · Federal grants in Virginia